Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250)

Market Cap	5.29T
Revenue (ttm)	220.74B
Net Income (ttm)	-11.40B
Shares Out	23.26M
EPS (ttm)	-490.31
PE Ratio	n/a
Forward PE	n/a
Dividend	200.00 (0.10%)
Ex-Dividend Date	n/a

Volume	276,244
Average Volume	133,114
Open	233,500
Previous Close	227,500
Day's Range	230,000 - 249,000
52-Week Range	89,300 - 268,500
Beta	1.75
RSI	60.65
Earnings Date	Nov 28, 2025

About Sam Chun Dang Pharm.

Sam Chun Dang Pharm. Co., Ltd engages in the manufacturing and sale of pharmaceutical products in South Korea. It provides ethical and over the counter products in various therapeutic areas comprising ophthalmology, cardiovascular, endocrinology, antibacterial, anti-fungal, antiviral, respiratory, anti-inflammatory, antihistamine, and musculoskeletal products, as well as vitamins and gastro intestine products. The company is also involved in exporting activities. Sam Chun Dang Pharm. Co., Ltd was founded in 1943 and is headquartered in Seoul, S...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1943
• Employees: 422
• Stock Exchange: KOSDAQ
• Ticker Symbol: 000250

Financial Performance

In 2024, Sam Chun Dang Pharm.'s revenue was 210.92 billion, an increase of 9.47% compared to the previous year's 192.67 billion. Losses were -10.92 billion, 5.14% more than in 2023.